The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global drug abuse testing market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Drug abuse is the deliberate consumption of illegal substances or overindulgence of prescribed psychoactive or performance-enhancing chemicals and over-the-counter (OTC) medications. It can affect the mind and body and lead to various disorders like addiction. As a result, it is diagnosed among individuals using different testing methods to provide effective treatment for related disorders. Drug abuse testing also assists in managing acute mental status and seizure cases in the emergency room and identifying children and newborns at risk of exposure to illicit drugs. Nowadays, it finds application in workplaces before hiring an applicant.
Presently, drugs like opiates, cannabinoids, cocaine, lysergic acid diethylamide (LSD), barbiturates, amphetamines, alcohol, diazepam, and ketamine are abused for their mind-altering characteristics, non-therapeutic and medicinal uses, and other purposes, including weight loss and enhancing athletic performance. This can lead to drug dependence and substance use disorder, which represents one of the key factors driving the demand for drug abuse testing across the globe. Apart from this, drug abuse can create significant safety and health hazards and decrease the productivity and morale of an individual. This, in turn, is positively influencing the use of drug abuse testing to screen employees and job applicants, provide a safe workplace, and comply with strict government laws and regulations. Moreover, substantial growth in pain management and opioid dependency clinics is catalyzing the demand for urine drug testing worldwide. Furthermore, leading companies are offering automated testing and analysis for drugs of abuse. These companies are also offering at-home use kits for instant drug abuse tests. This, along with the thriving e-commerce industry, is impelling the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global drug abuse testing market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, sample and end user.
Breakup by Product:
Breakup by Sample:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings, Omega Laboratories Inc., Quest Diagnostics Incorporated, Siemens AG, Thermo Fisher Scientific Inc. and United States Drug Testing Laboratories Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Sample, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings, Omega Laboratories Inc., Quest Diagnostics Incorporated, Siemens AG, Thermo Fisher Scientific Inc. and United States Drug Testing Laboratories Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at